Skip to main content
Our approach AI-Powered Pharma Tech

How we are
different

We have created a premier AI-Powered Pharma Tech and Services fund for early-stage companies. Pharma Tech is the evolutionary progression of healthcare software and tech-enabled services to vastly improve time to market and effectiveness within the Pharmaceutical industry.

Six principles

An interdisciplinary team identifying highly valued Pharma Tech companies in a shortened time frame to a sale, while maximizing investment return

01

Focused sector strategy

We invest exclusively in Pharma Tech, B2B SaaS and tech-enabled services with capital-efficient models built to scale. We don’t dabble outside our circle.

02

Operator-investor DNA

Our team has launched, financed, scaled, and exited Pharma Tech companies. We bring that operating experience to every portfolio company, hands-on.

03

Proprietary deal engine

Two decades operating in Pharma Tech and SaaS services has built a sourcing pipeline competitors can’t replicate.

04

Lead and co-lead positioning

We invest at seed and Series A with initial checks of $500K–$2M, typically leading or co-leading the round, setting terms, and taking a board seat to drive value from day one.

05

Strategic investor network

Our investors are pharma, provider, and payer decision-makers, your potential customers and acquirers, turning network access into commercial traction and exit pathways.

06

Hands-on company building

Roll-up-your-sleeves operational support: go-to-market, BD, financing, hiring, governance. We compress the time from inception to scale to sale.

How we think

Asymmetric moves in a crowded sector

Most healthcare investors spread bets across delivery, payers, and biotech. We don’t. By concentrating exclusively on Pharma Tech, we back the founders whose moats compound fastest.

Our network

Investors and advisors drawn from pharma, providers, and payers, working alongside our portfolio

Pharma execs
Health systems
Payer leaders
Strategic CROs
Providers
Med-device
Digital health
Clinical research